Navigation Links
Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Date:3/20/2011

veness of pixantrone, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, the PIX-R trial may not be posted to the website www.clinicaltrials.gov in the near future, that CTI may not have 60 sites open for enrollment by the end of April 2011, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics Addresses Recent Market Activity
2. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
3. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
4. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
5. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
8. MDAs Augies Quest Expands Testing of Potential ALS Therapeutics With New $2 Million Grant to ALS TDI
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
11. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Jose, California (PRWEB) May 06, 2015 ... Quantum Dots, a type of nanomaterial with diameter ... fastest-growing product in the global nanophotonics materials market. ... of quantum dots due to quantum confinement effect ... in a wide range of scientific, technological, and ...
(Date:5/6/2015)... May 6, 2015  Oxis Biotech, Inc. (OXIS), a ... OXI.PA, announced today that Cassian Yee , M.D., ... Medicine at the University of Texas MD Anderson Cancer ... also Professor, Department of Immunology, Division of Cancer Medicine, ... Immunology Research at the University of Texas MD Anderson ...
(Date:5/6/2015)... SHANGHAI , May 6, 2015 Dr ... institute of Massey University, will deliver a speech at the ... 24-25 at the Shanghai New Expo Center.  ... he will introduce to attendees the topic: ,Potato Starch: ... Bulk-ingredients and Smart Foods., Co-editor of a ...
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
Breaking Biology Technology:Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... - Sales up 16% - Profit Before R&D up 19% - Net Profit (Group Share) up 12% - ... approved the 2007 consolidated financial statements:, (EUR millions) 2007 ... ... sales % change, Sales ...
... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
... 12 Mercury Therapeutics,Inc. (MTI), a company that ... announces that it has signed an exclusive license,agreement ... Under this agreement, MTI has licensed to ... AMP-activated protein kinase (AMPK), a well,validated drug target ...
Cached Biology Technology:STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 2STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 3Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 2Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 3
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... (Washington, D.C. - Sept. 18, 2008) Nanotechnology opens ... and environmental applications. To ensure nanotechnology is developed ... (NSF) and EPA awarded $38 million to establish ... (CEINs). EPA contributed $5 million to the overall ...
... grant in excess of $2 million from the U.S. Air ... to fly that minimizes health complications to injured soldiers due ... a safe zone. "There is a sense of ... environment," explains Col. Warren Dorlac, MD, co-principal investigator on the ...
... press release is available in German . ... above all at airports has been increased considerably. ... of passengers. Possibilities for new and safe methods of transport ... be used for this purpose, however, it has to be ...
Cached Biology News:Nanotechnology: A brave new world requires bold new research approaches 2US Air Force grant targets medical evacuation procedures 2US Air Force grant targets medical evacuation procedures 3US Air Force grant targets medical evacuation procedures 4Checking people at airports -- with terahertz radiation 2
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Biology Products: